» Articles » PMID: 25932852

Obstetric and Neonatal Outcomes After Antipsychotic Medication Exposure in Pregnancy

Overview
Journal Obstet Gynecol
Date 2015 May 2
PMID 25932852
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Antipsychotic medications are used by increasing numbers of women of reproductive age. The safety of these medications during pregnancy has not been well described. We undertook a systematic review and meta-analysis of the adverse obstetric and neonatal outcomes associated with exposure to antipsychotics during pregnancy.

Data Sources: PubMed, Reprotox, and ClinicalTrials.gov were searched to identify potential studies for inclusion.

Methods Of Study Selection: Case-control or cohort studies estimating adverse birth outcomes associated with antipsychotic exposure during pregnancy were included. Pooled odds ratios (ORs) were used for dichotomous outcomes and weighted mean differences were used for neonatal birth weight and gestational age. Thirteen cohort studies, including 6,289 antipsychotic-exposed and 1,618,039 unexposed pregnancies, were included.

Tabulation, Integration, And Results: Antipsychotic exposure was associated with an increased risk of major malformations (absolute risk difference [ARD] 0.03, 95% confidence interval [CI] 0.00-0.05, P=.04, Z=2.06), heart defects (ARD 0.01, 95% CI 0.00-0.01, P<.001, Z=3.44), preterm delivery (ARD 0.05, 95% CI 0.03-0.08, P<.001, Z=4.10), small-for-gestational-age births (ARD 0.05, 95% CI 0.02-0.09, P=.006, Z=2.74), elective termination (ARD 0.09, 95% CI 0.05-0.13, P<.001, Z=4.69), and decreased birth weight (weighted mean difference -57.89 g, 95% CI -103.69 to -12.10 g, P=.01). There was no significant difference in the risk of major malformations (test for subgroup differences: χ²=0.07, degrees of freedom=1, P=.79) between typical (OR 1.55, 95% CI 1.21-1.99, P=.006) and atypical (OR 1.39, 95% CI 0.66-2.93, P=.38) antipsychotic medications. Antipsychotic exposure was not associated with risk of large-for-gestational-age births, stillbirth, and spontaneous abortion. Although antipsychotic exposure during pregnancy was associated with increased risk of adverse obstetric and neonatal outcomes, this association does not necessarily imply causation. This analysis was limited by the small number of included studies and limited adjustment in studies for possible confounders.

Conclusion: Women requiring antipsychotic treatment during pregnancy appear at higher risk of adverse birth outcomes, regardless of causation, and may benefit from close monitoring and minimization of other potential risk factors during pregnancy.

Citing Articles

Comparative Safety of Antipsychotic Medications and Mood Stabilizers During Pregnancy: A Systematic Review and Network Meta-analysis of Congenital Malformations and Prenatal Outcomes.

Wang E, Liu Y, Wang Y, Han X, Zhou Y, Zhang L CNS Drugs. 2024; 39(1):1-22.

PMID: 39528870 PMC: 11695384. DOI: 10.1007/s40263-024-01131-x.


Neonatal outcomes after in utero exposure to antipsychotics: a systematic review and meta-analysis.

Joseph-Delaffon K, Eletri L, Dechartres A, Nordeng H, Richardson J, Elefant E Eur J Epidemiol. 2024; 39(10):1073-1096.

PMID: 39352602 DOI: 10.1007/s10654-024-01156-y.


Risk of congenital malformations associated with first-trimester exposure to antipsychotics: A propensity score-weighted population-based cohort study.

Chan J, Lee K, Wong C, Chang W Eur Psychiatry. 2024; 67(1):e42.

PMID: 38800849 PMC: 11441336. DOI: 10.1192/j.eurpsy.2024.1758.


Is Antipsychotic Drug Use During Pregnancy Associated with Increased Malformation Rates and Worsening of Maternal and Infant Outcomes? A Systematic Review.

Sani G, Callovini T, Ferrara O, Segatori D, Margoni S, Simonetti A Curr Neuropharmacol. 2024; 22(14):2402-2421.

PMID: 38766824 PMC: 11451318. DOI: 10.2174/1570159X22666240516151449.


Risk factors for preterm birth: an umbrella review of meta-analyses of observational studies.

Mitrogiannis I, Evangelou E, Efthymiou A, Kanavos T, Birbas E, Makrydimas G BMC Med. 2023; 21(1):494.

PMID: 38093369 PMC: 10720103. DOI: 10.1186/s12916-023-03171-4.


References
1.
Lieberman 3rd J . Metabolic changes associated with antipsychotic use. Prim Care Companion J Clin Psychiatry. 2005; 6(Suppl 2):8-13. PMC: 487012. View

2.
Shapiro S, Heinonen O, Siskind V, Kaufman D, Monson R, Slone D . Antenatal exposure to doxylamine succinate and dicyclomine hydrochloride (Benedectin) in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol. 1977; 128(5):480-5. DOI: 10.1016/0002-9378(77)90028-x. View

3.
Reichman N, Hade E . Validation of birth certificate data. A study of women in New Jersey's HealthStart program. Ann Epidemiol. 2001; 11(3):186-93. DOI: 10.1016/s1047-2797(00)00209-x. View

4.
Wyszynski D, Nambisan M, Surve T, Alsdorf R, Smith C, Holmes L . Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology. 2005; 64(6):961-5. DOI: 10.1212/01.WNL.0000154516.43630.C5. View

5.
. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008; 111(4):1001-20. DOI: 10.1097/AOG.0b013e31816fd910. View